Developer docs
API playgroundTry for free, no card

Search company profiles

CUBRC

Full company profile

uuid000bzph

Namestring
CUBRC
Legal namestring
CUBRC, Inc.
Websiteurl
cubrc.org
Company typeenum
Private
Founded yearint
1983
Descriptiontext

CUBRC is an independent, not-for-profit 501(c)(3) research and development corporation founded in 1983 and headquartered in Buffalo, New York, with additional offices in Rome NY, San Diego CA, and Dayton OH. The company executes research, development, testing, and systems integration for the U.S. Defense, Intelligence, and Homeland Security communities across three operating sectors: Hypersonics & Aerosciences, Data Science & Information Fusion, and Chemical/Biological/Medical Sciences.

CUBRC's core technology assets include the LENS family of hypersonic ground test facilities (LENS 48-Inch Tunnel, LENS I, LENS II, and LENS XX), which are designated critical US Government test infrastructure and represent the nation's largest velocity-versus-altitude test capability, including the only domestic hypervelocity expansion driven wind tunnel. The Data Science sector produces the RTI mission planning suite, ICED information fusion framework, SITA threat assessment tool, and the Common Core Ontology (CCO), which has been adopted as a baseline standard by both the DoD and the Intelligence Community. The CBRND sector operates BSL-2/BSL-3 laboratories under the Federal Select Agent Program, chemical defense test facilities certified by the U.S. Army Materiel Command, and an ISO 9001:2015-certified quality management system. CUBRC's wholly-owned subsidiary Avarint, LLC develops and maintains the DIADS (Digital Integrated Air Defense System) high-fidelity simulation for the U.S. Air Force.

The company's revenue model is exclusively professional services-based, generating revenue through federal government contracts (competitive procurements, sole-source awards, and SBIR/STTR partnerships) with agencies including DoD, USAF, AFOSR, FDA, NIH, NIAID, BARDA, and DHS. As a not-for-profit, CUBRC accesses non-dilutive funding programs and serves as a transition partner for small businesses. Recent contract wins include a $96M 10-year CHAC IDIQ to Avarint (December 2025), $16M in FY2020 DoD facility funding, and a $2M FDA contract (October 2024). In April 2024, CUBRC made its first acquisition, Ahmic Aerospace, expanding its aerosciences division into the Ohio Aerospace Corridor.

Short descriptiontext

CUBRC is a not-for-profit R&D corporation serving U.S. Defense, Intelligence, and Homeland Security agencies through hypersonic testing (LENS facilities), data fusion/AI tools, and chemical-biological defense laboratories. It operates via federal contracts and wholly-owned subsidiary Avarint.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBuffalo, United States
HQ citystring
Buffalo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hypersonic ground testing, data fusion systems, chemical biological defense, aerospace research development, mission planning optimization
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Engineering Services541330
SIC code3 codes
  • Services-Testing Laboratories8734
  • Services-Engineering Services8711
  • Services-Commercial Physical & Biological Research8731
Product category
Defense Research & Development Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Government Research & Development Contracts
TypeProfessional Services
Description

CUBRC generates revenue through federal government contracts for research, development, testing, and systems integration services. As a not-for-profit 501(c)(3), the company accesses non-dilutive funding from agencies including DoD, FDA, NIH, NIAID, BARDA, and Department of Homeland Security. Revenue comes from competitive procurements, sole-source awards, and SBIR/STTR partnerships.

cubrc.org
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Avarint
Description

A CUBRC subsidiary specializing in C4ISR Modeling and Simulation, developing and maintaining the Digital Integrated Air Defense System (DIADS) for the US Air Force.

cubrc.org
+1 more record
Core offering1 text field

CUBRC is an independent not-for-profit research and development company that executes research, development, testing, and systems integration for the U.S. Defense, Intelligence, and Homeland Security communities. Its work spans three sectors: Hypersonics & Aerosciences (operating the LENS family of shock tunnels), Data Science & Information Fusion (mission planning, ontology, ML/AI tools), and Chemical, Biological & Medical Sciences (BSL-2/BSL-3 labs and chemical defense test facilities). The company also operates wholly-owned subsidiary Avarint for C4ISR modeling and simulation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • LENS XX provides nation’s only hypervelocity expansion driven wind tunnel capability achieving 10k-30k ft/sec velocities for reentry and extreme hypersonic flight evaluation
+1 more record
Product overview1 text field

CUBRC is an independent not-for-profit research and development company organized into three primary business sectors: Hypersonics & Aerosciences, Data Science & Information Fusion, and Chemical, Biological & Medical Sciences. The Hypersonics & Aerosciences sector operates the LENS family of ground test facilities (LENS 48-Inch Tunnel, LENS I, LENS II, and LENS XX) providing hypersonic flow testing capabilities from Mach 2-18. The Data Science & Information Fusion sector offers the RTI (RIGORS/TEMPO/INTELLEX) mission planning suite, ICED and SITA information fusion tools, and the Common Core Ontology (CCO) for knowledge representation. Through its wholly-owned subsidiary Avarint, CUBRC maintains the DIADS simulation system and operates chemical defense test facilities. The April 2024 acquisition of Ahmic Aerospace added aerospace sensors and instrumentation capabilities. The Chemical, Biological & Medical Sciences sector provides BSL-2/BSL-3 laboratory facilities for research, testing, and medical countermeasure development.

Product and service12 records
1LENS 48-Inch Tunnel
CategoryHypersonic Test Facility
Description

Hypersonic ground test facility capable of unique altitude versus velocity matching freestream conditions from Mach 6 to 9 and Mach number versus Reynolds number matching from Mach 6 to 18; in continuous operation since the 1950s.

2LENS I
CategoryHypersonic Test Facility
Description

Hypersonic ground test facility completed in 1992 for full-scale testing and evaluation of atmospheric hypersonic interceptor systems; supports Mach 6 to 10 and Reynolds number matching from Mach 6 to 18.

3LENS II
CategoryHypersonic Test Facility
Description

Hypersonic ground test facility completed in 1998 for testing larger flight articles at lower Mach numbers, supporting Mach 3 to 8 altitude vs. velocity matching and Mach 3 to 10 Reynolds number matching (down to Mach 2 in Ludwieg mode).

4LENS XX
CategoryHypersonic Test Facility
Description

Hypervelocity expansion driven wind tunnel facility added in 2008, providing access to velocities from 10k to 30k ft/sec to evaluate high temperature Real Gas effects for reentry and extreme hypersonic flight.

5RIGORS/TEMPO/INTELLEX (RTI) Suite
CategoryMission Planning Software
Description

Mission planning and optimization suite developed under Office of Naval Research (ONR) funding that combines advanced operations research algorithms, machine learning, and complex event-processing for semi-autonomous Command and Control.

6ICED (Information Consumption Exploitation & Dissemination)
CategoryInformation Fusion Software
Description

Tool suite providing robust framework for integration and harmonization of multiple disparate data sources to a common core ontology, with customizable fusion/analytics and RDF triple/graph-based storage using cloud-based Rya.

7SITA (Situation Identification and Threat Assessment)
CategoryInformation Fusion Software
Description

Multi-function holistic information fusion capability combining raw measurement data, subject matter expertise, and contextual information into operational decision-quality information with predictive capabilities.

8Common Core Ontology (CCO)
CategoryData Ontology Standard
Description

Ontology based on the ISO standard Basic Formal Ontology (BFO) providing structured knowledge representation for interoperability, integration, and data sharing across domains; released open-source under BSD license and adopted as the DoD and Intelligence Community baseline standard for formal ontology.

9DIADS (Digital Integrated Air Defense System)
CategoryC4ISR Modeling & Simulation
Description

High-fidelity mission-level simulation of Integrated Air Defense Systems (IADS), developed and maintained by CUBRC's subsidiary Avarint for the U.S. Air Force, modeling potential enemy radar and missile systems for military training simulations.

10Chemical Defense Test Facilities
CategoryChemical Defense Testing
Description

State-of-the-art chemical test facilities operated by Avarint, certified by the U.S. Army Materiel Command (AMC), enabling live chemical warfare agent testing for detection, decontamination, and personal/collective protection systems.

11BSL-2 and BSL-3 Laboratory Facilities
CategoryBiological Laboratory Facilities
Description

Biosafety Level 2 and 3 laboratory facilities permitted under the Federal Select Agent Program, supporting RDT&E in microbiology, virology, molecular biology, method development, biological detection, decontamination, and individual/collective protection; includes aerobiology with aerosol test chambers ranging from 1.3 m³ to 600 m³.

12Ahmic Aerospace Sensors and Instrumentation
CategoryAerospace Sensors & Instrumentation
Description

Aerospace measurement techniques and instrumentation for hypersonic ground and flight testing, developed by Ahmic Aerospace in Dayton, Ohio, and acquired by CUBRC in April 2024.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-24
Description

CUBRC collaborates with EpiVax, Inc. on FDA-funded research programs for immunogenicity risk assessment of generic peptide drugs. The partnership has produced multiple FDA contracts including a $2M award (October 2024) for developing control peptides for T-cell assay standardization supporting generic drug ANDA applications. EpiVax brings immunogenicity assessment expertise using EpiMatrix and JanusMatrix computational tools.

Strategic tierCoreTypeOthers
Description

FDA sponsors research through CUBRC for immunogenicity assessment of generic peptide drugs, including recent $2M contract for control peptide development. FDA scientists co-authored published research with CUBRC on teriparatide impurity immunogenicity risks.

Strategic tierMajorTypeOthers
Description

NIH provides funding for medical countermeasure development programs through CUBRC, supporting the chemical and biological defense portfolio and public health applications.

Strategic tierMajorTypeOthers
Description

National Institute of Allergy and Infectious Diseases partners with CUBRC on infectious disease research and medical countermeasure development.

5BARDA
Strategic tierMajorTypeOthers
Description

Biomedical Advanced Research and Development Authority partners with CUBRC for advanced development of medical countermeasures against public health threats.

cubrc.org
Strategic tierCoreTypeOthers
Description

DoD is the primary customer for CUBRC's hypersonics, chemical/biological defense, and information fusion programs. Recent $16M funding for LENS facility upgrades and ongoing support for T&E/S&T programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Texas A&M served as co-Principal Investigator with CUBRC on the AFOSR-sponsored BOLT II hypersonic sounding rocket flight program, contributing to boundary layer transition research.

8Air Force Office of Scientific Research (AFOSR)
Strategic tierCoreTypeOthers
Description

AFOSR sponsors the BOLT II flight test program in which CUBRC participates, providing funding for hypersonic boundary layer transition research.

cubrc.org
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

NASA Wallops served as launch provider for the BOLT II hypersonic sounding rocket, working with CUBRC on vehicle delivery and flight operations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ahmic Aerospace was acquired by CUBRC in April 2024 as its first acquisition. Based in Dayton, OH, Ahmic specializes in aerospace measurement techniques and instrumentation, expanding CUBRC's hypersonic testing capabilities. Operations and staff remain in Dayton as the Ahmic Sensors Group.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CUBRC

Defense Research & Development Servicescubrc.org

CUBRC is a not-for-profit R&D corporation serving U.S. Defense, Intelligence, and Homeland Security agencies through hypersonic testing (LENS facilities), data fusion/AI tools, and chemical-biological defense laboratories. It operates via federal contracts and wholly-owned subsidiary Avarint.

What CUBRC does

CUBRC is an independent, not-for-profit 501(c)(3) research and development corporation founded in 1983 and headquartered in Buffalo, New York, with additional offices in Rome NY, San Diego CA, and Dayton OH. The company executes research, development, testing, and systems integration for the U.S. Defense, Intelligence, and Homeland Security communities across three operating sectors: Hypersonics & Aerosciences, Data Science & Information Fusion, and Chemical/Biological/Medical Sciences.

CUBRC's core technology assets include the LENS family of hypersonic ground test facilities (LENS 48-Inch Tunnel, LENS I, LENS II, and LENS XX), which are designated critical US Government test infrastructure and represent the nation's largest velocity-versus-altitude test capability, including the only domestic hypervelocity expansion driven wind tunnel. The Data Science sector produces the RTI mission planning suite, ICED information fusion framework, SITA threat assessment tool, and the Common Core Ontology (CCO), which has been adopted as a baseline standard by both the DoD and the Intelligence Community. The CBRND sector operates BSL-2/BSL-3 laboratories under the Federal Select Agent Program, chemical defense test facilities certified by the U.S. Army Materiel Command, and an ISO 9001:2015-certified quality management system. CUBRC's wholly-owned subsidiary Avarint, LLC develops and maintains the DIADS (Digital Integrated Air Defense System) high-fidelity simulation for the U.S. Air Force.

The company's revenue model is exclusively professional services-based, generating revenue through federal government contracts (competitive procurements, sole-source awards, and SBIR/STTR partnerships) with agencies including DoD, USAF, AFOSR, FDA, NIH, NIAID, BARDA, and DHS. As a not-for-profit, CUBRC accesses non-dilutive funding programs and serves as a transition partner for small businesses. Recent contract wins include a $96M 10-year CHAC IDIQ to Avarint (December 2025), $16M in FY2020 DoD facility funding, and a $2M FDA contract (October 2024). In April 2024, CUBRC made its first acquisition, Ahmic Aerospace, expanding its aerosciences division into the Ohio Aerospace Corridor.

CUBRC firmographics

Firmographics
Name
CUBRC
Legal name
CUBRC, Inc.
Website
https://cubrc.org
Company type
Private
Founded year
1983
Operating status
Operating
Headcount range
51–100 employees
Short description
CUBRC is a not-for-profit R&D corporation serving U.S. Defense, Intelligence, and Homeland Security agencies through hypersonic testing (LENS facilities), data fusion/AI tools, and chemical-biological defense laboratories. It operates via federal contracts and wholly-owned subsidiary Avarint.
Ownership category
akta.pro rank

Where CUBRC is headquartered

Location

Headquarters

HQ city
Buffalo
HQ country
United States
HQ region
North America

Offices4 records

Markets served

CUBRC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Government Research & Development Contracts: CUBRC generates revenue through federal government contracts for research, development, testing, and systems integration services. As a not-for-profit 501(c)(3), the company accesses non-dilutive funding from agencies including DoD, FDA, NIH, NIAID, BARDA, and Department of Homeland Security. Revenue comes from competitive procurements, sole-source awards, and SBIR/STTR partnerships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

CUBRC product offering

Product offering

Core offering

CUBRC is an independent not-for-profit research and development company that executes research, development, testing, and systems integration for the U.S. Defense, Intelligence, and Homeland Security communities. Its work spans three sectors: Hypersonics & Aerosciences (operating the LENS family of shock tunnels), Data Science & Information Fusion (mission planning, ontology, ML/AI tools), and Chemical, Biological & Medical Sciences (BSL-2/BSL-3 labs and chemical defense test facilities). The company also operates wholly-owned subsidiary Avarint for C4ISR modeling and simulation.

Product overview

CUBRC is an independent not-for-profit research and development company organized into three primary business sectors: Hypersonics & Aerosciences, Data Science & Information Fusion, and Chemical, Biological & Medical Sciences. The Hypersonics & Aerosciences sector operates the LENS family of ground test facilities (LENS 48-Inch Tunnel, LENS I, LENS II, and LENS XX) providing hypersonic flow testing capabilities from Mach 2-18. The Data Science & Information Fusion sector offers the RTI (RIGORS/TEMPO/INTELLEX) mission planning suite, ICED and SITA information fusion tools, and the Common Core Ontology (CCO) for knowledge representation. Through its wholly-owned subsidiary Avarint, CUBRC maintains the DIADS simulation system and operates chemical defense test facilities. The April 2024 acquisition of Ahmic Aerospace added aerospace sensors and instrumentation capabilities. The Chemical, Biological & Medical Sciences sector provides BSL-2/BSL-3 laboratory facilities for research, testing, and medical countermeasure development.

Differentiator

Problem solved

Functional benefit

Brands

  • Avarint: A CUBRC subsidiary specializing in C4ISR Modeling and Simulation, developing and maintaining the Digital Integrated Air Defense System (DIADS) for the US Air Force.
  • Ahmic Sensors Group

Products and services

  • LENS 48-Inch Tunnel Hypersonic ground test facility capable of unique altitude versus velocity matching freestream conditions from Mach 6 to 9 and Mach number versus Reynolds number matching from Mach 6 to 18; in continuous operation since the 1950s.
  • LENS I Hypersonic ground test facility completed in 1992 for full-scale testing and evaluation of atmospheric hypersonic interceptor systems; supports Mach 6 to 10 and Reynolds number matching from Mach 6 to 18.
  • LENS II Hypersonic ground test facility completed in 1998 for testing larger flight articles at lower Mach numbers, supporting Mach 3 to 8 altitude vs. velocity matching and Mach 3 to 10 Reynolds number matching (down to Mach 2 in Ludwieg mode).
  • LENS XX Hypervelocity expansion driven wind tunnel facility added in 2008, providing access to velocities from 10k to 30k ft/sec to evaluate high temperature Real Gas effects for reentry and extreme hypersonic flight.
  • RIGORS/TEMPO/INTELLEX (RTI) Suite Mission planning and optimization suite developed under Office of Naval Research (ONR) funding that combines advanced operations research algorithms, machine learning, and complex event-processing for semi-autonomous Command and Control.
  • ICED (Information Consumption Exploitation & Dissemination) Tool suite providing robust framework for integration and harmonization of multiple disparate data sources to a common core ontology, with customizable fusion/analytics and RDF triple/graph-based storage using cloud-based Rya.
  • SITA (Situation Identification and Threat Assessment) Multi-function holistic information fusion capability combining raw measurement data, subject matter expertise, and contextual information into operational decision-quality information with predictive capabilities.
  • Common Core Ontology (CCO) Ontology based on the ISO standard Basic Formal Ontology (BFO) providing structured knowledge representation for interoperability, integration, and data sharing across domains; released open-source under BSD license and adopted as the DoD and Intelligence Community baseline standard for formal ontology.
  • DIADS (Digital Integrated Air Defense System) High-fidelity mission-level simulation of Integrated Air Defense Systems (IADS), developed and maintained by CUBRC's subsidiary Avarint for the U.S. Air Force, modeling potential enemy radar and missile systems for military training simulations.
  • Chemical Defense Test Facilities State-of-the-art chemical test facilities operated by Avarint, certified by the U.S. Army Materiel Command (AMC), enabling live chemical warfare agent testing for detection, decontamination, and personal/collective protection systems.
  • BSL-2 and BSL-3 Laboratory Facilities Biosafety Level 2 and 3 laboratory facilities permitted under the Federal Select Agent Program, supporting RDT&E in microbiology, virology, molecular biology, method development, biological detection, decontamination, and individual/collective protection; includes aerobiology with aerosol test chambers ranging from 1.3 m³ to 600 m³.
  • Ahmic Aerospace Sensors and Instrumentation Aerospace measurement techniques and instrumentation for hypersonic ground and flight testing, developed by Ahmic Aerospace in Dayton, Ohio, and acquired by CUBRC in April 2024.

Quantifiable outcome

  • LENS XX provides nation’s only hypervelocity expansion driven wind tunnel capability achieving 10k-30k ft/sec velocities for reentry and extreme hypersonic flight evaluation
  • +1 more outcomes

Companies that use CUBRC

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

CUBRC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

CUBRC partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and minor.

  • EpiVax, Inc.coreStrategic or Co-development Partner · 24 October 2024CUBRC collaborates with EpiVax, Inc. on FDA-funded research programs for immunogenicity risk assessment of generic peptide drugs. The partnership has produced multiple FDA contracts including a $2M award (October 2024) for developing control peptides for T-cell assay standardization supporting generic drug ANDA applications. EpiVax brings immunogenicity assessment expertise using EpiMatrix and JanusMatrix computational tools.
  • Food and Drug Administration (FDA)coreOthersFDA sponsors research through CUBRC for immunogenicity assessment of generic peptide drugs, including recent $2M contract for control peptide development. FDA scientists co-authored published research with CUBRC on teriparatide impurity immunogenicity risks.
  • National Institutes of Health (NIH)majorOthersNIH provides funding for medical countermeasure development programs through CUBRC, supporting the chemical and biological defense portfolio and public health applications.
  • NIAIDmajorOthersNational Institute of Allergy and Infectious Diseases partners with CUBRC on infectious disease research and medical countermeasure development.
  • BARDAmajorOthersBiomedical Advanced Research and Development Authority partners with CUBRC for advanced development of medical countermeasures against public health threats.
  • U.S. Department of DefensecoreOthersDoD is the primary customer for CUBRC's hypersonics, chemical/biological defense, and information fusion programs. Recent $16M funding for LENS facility upgrades and ongoing support for T&E/S&T programs.
  • Texas A&M UniversityminorStrategic or Co-development PartnerTexas A&M served as co-Principal Investigator with CUBRC on the AFOSR-sponsored BOLT II hypersonic sounding rocket flight program, contributing to boundary layer transition research.
  • Air Force Office of Scientific Research (AFOSR)coreOthersAFOSR sponsors the BOLT II flight test program in which CUBRC participates, providing funding for hypersonic boundary layer transition research.
  • NASA Wallops Flight FacilityminorImplementation/ SI/ Consulting PartnerNASA Wallops served as launch provider for the BOLT II hypersonic sounding rocket, working with CUBRC on vehicle delivery and flight operations.
  • Ahmic AerospacecoreStrategic or Co-development PartnerAhmic Aerospace was acquired by CUBRC in April 2024 as its first acquisition. Based in Dayton, OH, Ahmic specializes in aerospace measurement techniques and instrumentation, expanding CUBRC's hypersonic testing capabilities. Operations and staff remain in Dayton as the Ahmic Sensors Group.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

CUBRC competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

CUBRC social profiles

Digital presence

CUBRC compliance and trust

Trust signal

Compliance1 record

CUBRC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CUBRC leadership team

Management profile

Number of profiles

Profiles8 records

CUBRC subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

CUBRC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CUBRC M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CUBRC

What does CUBRC do?

CUBRC is an independent not-for-profit research and development company that executes research, development, testing, and systems integration for the U.S. Defense, Intelligence, and Homeland Security communities. Its work spans three sectors: Hypersonics & Aerosciences (operating the LENS family of shock tunnels), Data Science & Information Fusion (mission planning, ontology, ML/AI tools), and Chemical, Biological & Medical Sciences (BSL-2/BSL-3 labs and chemical defense test facilities). The company also operates wholly-owned subsidiary Avarint for C4ISR modeling and simulation.

Is CUBRC a public or private company?

CUBRC is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CUBRC founded?

CUBRC was founded in 1983. It employs 51 to 100 people.

Where is CUBRC based?

CUBRC is headquartered in Buffalo, United States, in the North America region.

How does CUBRC make money?

One revenue line is on record: government Research & Development Contracts.

Does CUBRC have an API?

No public API is recorded for CUBRC.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsCUBRC subsidiary lands $96M Air Force hypersonic systems dealThe article title reports that a subsidiary of CUBRC secured a $96 million contract from the U.S. Air Force for hypersonic systems. The provided body text is limited to generic boilerplate and subscription prompts, lacking specific details about the event or entities beyond the title.AiaaBOLT II Vehicle Design, Instrumentation, and Ground Test Comparisons to FlightThe Air Force Office of Scientific Research and the Air Force Research Laboratory funded the BOLT II hypersonic flight experiment, led by Texas A&M University and CUBRC, to study boundary-layer turbulence in complex geometries. The mission launched on March 21, 2022, from NASA Wallops via a suborbital sounding rocket, marking the first full-scale hypersonic vehicle tested in a wind tunnel prior to flight. This paper details the vehicle design, instrumentation, and ground test comparisons against flight data for both natural and forced transition experiments.PR NewswireEpiVax y CUBRC obtienen contrato con la FDA para el desarrollo de péptidos de controlEpiVax, Inc. and CUBRC, Inc. have been awarded a two-year contract by the FDA's Office of Generic Drugs valued at $2 million to develop standardized peptide controls for immunogenicity risk assessments. This initiative aims to establish new industry standards to support the regulatory approval of generic peptide drugs, such as those similar to Ozempic and Wegovy. The collaboration builds on previous FDA-funded research to improve the safety and efficacy evaluation of synthetic peptide medications.PR NewswireEpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide DrugsEpiVax and CUBRC have been awarded a two-year, $2 million contract from the FDA's Office of Generic Drugs to develop standardized control peptides for immunogenicity risk assessment assays. This collaboration aims to establish industry standards that enhance the specificity and sensitivity of methods used in applications for generic peptide drugs. The project builds on previous FDA-funded research by EpiVax regarding in silico and in vitro risk assessment techniques.PR NewswireEpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide DrugsEpiVax, Inc. and CUBRC, Inc. have been awarded a two-year, $2 million contract (#75F40124C00094) from the FDA's Office of Generic Drugs to develop standardized controls for T cell assays assessing immunogenicity risk of generic peptide drugs. The contract will establish industry standards to enhance specificity and sensitivity across assay methods for ANDA applications of generic peptide drugs such as teriparatide, exenatide, liraglutide, and tirzepatide. The collaboration builds on two previous FDA contracts and aims to improve access to affordable generic peptide therapeutics by helping developers and FDA reviewers differentiate higher-risk impurities from lower-risk ones.PR NewswireEpiVax et CUBRC remportent un contrat de la FDA d'une valeur de 2 millions de dollars pour le développement de peptides de contrôle pour les essais d'évaluation du risque d'immunogénicité soutenant leEpiVax, Inc. and CUBRC, Inc. have been awarded a $2 million two-year contract from the FDA's Office of Generic Drugs to develop standardized positive and negative peptide controls for T cell testing to evaluate immunogenicity risk in generic peptide drugs. The contract will establish new industry standards to improve the specificity and sensitivity of testing methods, supporting abbreviated new drug applications (ANDAs) for generic peptide medications including teripatide, exenatide, liraglutide, and tirzepatide. This collaboration builds on EpiVax's prior FDA-funded research, including the development of the "What-if Machine" algorithm for in silico peptide impurity risk assessment.PR NewswireEpiVax und CUBRC erhalten FDA-Auftrag im Wert von 2 Millionen Dollar für die Entwicklung von Kontrollpeptiden für Immunogenitäts-Risikobewertungstests zur Unterstützung von Zulassungsanträgen für geneEpiVax, Inc. and CUBRC, Inc. have received a two-year, $2 million contract from the FDA's Office of Generic Drugs (OGD) to develop standardized controls for T-cell tests used to assess the immunogenicity risk of generic peptide drugs supporting ANDA filings. The contract will support approval applications for generic peptide medications including Teriparatid, Exenatid, Liraglutid, and Tirzepatid, building on EpiVax's prior FDA-funded research including the What-if Machine (WhIM) algorithm for identifying high and low-risk impurities. The collaboration aims to establish new industry standards for immunogenicity assessment of generic peptide drugs, potentially facilitating broader access to affordable versions of branded medications like Ozempic and Wegovy.CubrcCUBRC Acquires Ahmic AerospaceCUBRC has acquired Ahmic Aerospace, a developer of instrumentation and measurement techniques for the aerospace industry, to expand its Aerosciences business capabilities. The integration aims to leverage combined technical expertise in hypersonic testing and computational modeling to enhance services for US Government and defense customers. Ahmic's operations will remain in Dayton, Ohio, while continuing to serve existing clients under the CUBRC umbrella.CubrcBiotech Non-Dilutive Funding & Consulting ServicesCUBRC describes its services to early- and mid-stage biotech and pharmaceutical companies, including proposal development, contract negotiation, program management and consulting on non-dilutive U.S. Government funding. The company cites over 35 years of experience with agencies such as NIH, FDA, BARDA and DoD, and offers testing in Biosafety Level 3 facilities. No financial figures or client names were disclosed.PR NewswireMicrobion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical PravibismaneMicrobion Corporation announced it received up to $2.1 million in non-dilutive funding from the US Navy via CUBRC, Inc. to advance an exploratory phase 2 proof-of-concept study for its topical drug pravibismane. The trial targets moderate to severe diabetic foot ulcer infections, with enrollment expected to begin in Q2 2022.